Proteasome inhibitors
Oncology· 2 reviewed drugs· 1749 cited findings behind them
What the regulatory reviews cover
The proteasome inhibitors in this library that have undergone regulatory review include Velcade and Ninlaro. These drugs were reviewed for various indications, such as the treatment of relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL), multiple myeloma, and mantle cell lymphoma.
Different drugs were studied in different trials, so the figures presented are not head-to-head comparisons. For Velcade, the Overall Response Rate (CR+PR) after 4 cycles (SC) was 43% (TAKEDA PHARMS USA — Velcade FDA Review, p.70). Ninlaro demonstrated a PFS (ixazomib arm, 1st interim analysis) of 20.6 months compared to a PFS (placebo arm, 1st interim analysis) of 14.7 months (TAKEDA PHARMS USA — Ninlaro FDA Summary Review (NDA/BLA 2084, p.8).
The drugs — one cited result each
| Velcade Johnson & Johnson | Overall Response Rate (CR+PR) after 4 cycles (SC): 43 TAKEDA PHARMS USA — Velcade FDA Review, p.70 |
| Ninlaro Takeda Pharmaceutical Company Limited | PFS (ixazomib arm, 1st interim analysis): 20.6 TAKEDA PHARMS USA — Ninlaro FDA Summary Review (NDA/BLA 2084, p.8 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.